Find a Clinical Trial

Find a Clinical Trial

Use the abbreviation for your state (ie. FL, TX, NV)
Search by practice name, trial titles, indicators and specific disease types.

Esophageal Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: NA
USOR Number: 15026

  • Practice Details

520 Country Club Rd
Eugene, Oregon 97401
P: (888) 384-9822

More Details View Practice Page

Esophageal Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Springfield

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: NA
USOR Number: 15026

  • Practice Details

3377 Riverbend Drive, Suite 500
Springfield, Oregon 97477
P: (888) 384-9822

More Details View Practice Page

Pancreatic Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Springfield

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: NA
USOR Number: 15026

  • Practice Details

3377 Riverbend Drive, Suite 500
Springfield, Oregon 97477
P: (888) 384-9822

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Springfield

A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

  • Details

ClinicalTrials.gov ID: NCT02924376
Diagnosis Type: NA
USOR Number: 16066

  • Practice Details

3377 Riverbend Drive, Suite 500
Springfield, Oregon 97477
P: (888) 384-9822

More Details View Practice Page

Pancreatic Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: NA
USOR Number: 15026

  • Practice Details

520 Country Club Rd
Eugene, Oregon 97401
P: (888) 384-9822

More Details View Practice Page

Fallopian Tube Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: NA
USOR Number: 15026

  • Practice Details

520 Country Club Rd
Eugene, Oregon 97401
P: (888) 384-9822

More Details View Practice Page

Fallopian Tube Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Springfield

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: NA
USOR Number: 15026

  • Practice Details

3377 Riverbend Drive, Suite 500
Springfield, Oregon 97477
P: (888) 384-9822

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Springfield

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: NA
USOR Number: 15026

  • Practice Details

3377 Riverbend Drive, Suite 500
Springfield, Oregon 97477
P: (888) 384-9822

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: NA
USOR Number: 15026

  • Practice Details

520 Country Club Rd
Eugene, Oregon 97401
P: (888) 384-9822

More Details View Practice Page

Lung Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

  • Details

ClinicalTrials.gov ID: NCT02574078
Diagnosis Type: NSCLC
USOR Number: 14158

  • Practice Details

520 Country Club Rd
Eugene, Oregon 97401
P: (888) 384-9822

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Eugene

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: NA
USOR Number: 15026

  • Practice Details

520 Country Club Rd
Eugene, Oregon 97401
P: (888) 384-9822

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Springfield

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: NA
USOR Number: 15026

  • Practice Details

3377 Riverbend Drive, Suite 500
Springfield, Oregon 97477
P: (888) 384-9822

More Details View Practice Page

Mesothelioma

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Springfield

Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93)

  • Details

ClinicalTrials.gov ID: NCT01907100
Diagnosis Type: NA
USOR Number: 15175

  • Practice Details

3377 Riverbend Drive, Suite 500
Springfield, Oregon 97477
P: (888) 384-9822

More Details View Practice Page

Rectal Cancer

Clinical Trial at: Willamette Valley Cancer Institute and Research Center - Springfield

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)

  • Details

ClinicalTrials.gov ID: NCT02555878
Diagnosis Type: NA
USOR Number: 15026

  • Practice Details

3377 Riverbend Drive, Suite 500
Springfield, Oregon 97477
P: (888) 384-9822

More Details View Practice Page

Pages